Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
Jason R.B. Dyck, Samuel Sossalla, Nazha Hamdani, et al.
Journal of Molecular and Cellular Cardiology (2022) Vol. 167, pp. 17-31
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Metabolic Communication by SGLT2 Inhibition
A. Billing, Young Chul Kim, Søren Gullaksen, et al.
Circulation (2023) Vol. 149, Iss. 11, pp. 860-884
Open Access | Times Cited: 60
Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis
Y J Youn, Seung Yeon Kim, Hyun‐Jeong Jeong, et al.
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101131-101131
Open Access | Times Cited: 24
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights
Carl Simela, John M. Walker, Arjun K. Ghosh, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 3
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 3
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, et al.
Pharmacology & Therapeutics (2025) Vol. 270, pp. 108861-108861
Open Access | Times Cited: 2
Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis
Jie Min, Lin Wu, Yandong Liu, et al.
Life Sciences (2022) Vol. 312, pp. 121207-121207
Closed Access | Times Cited: 43
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
João Sérgio Neves, Marta Borges‐Canha, Francisco Vasques‐Nóvoa, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 6, pp. 517-525
Closed Access | Times Cited: 33
Ketones and the cardiovascular system
Gary D. Lopaschuk, Jason R.B. Dyck
Nature Cardiovascular Research (2023) Vol. 2, Iss. 5, pp. 425-437
Open Access | Times Cited: 32
Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure
Vasiliki Tsigkou, Evangelos Oikonomou, Artemis Anastasiou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4321-4321
Open Access | Times Cited: 31
Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts
Nicolas Girerd, Christophe Leclercq, Olivier Hanon, et al.
Revista Española de Cardiología (English Edition) (2023) Vol. 76, Iss. 10, pp. 813-820
Open Access | Times Cited: 31
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies
Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1126-1126
Open Access | Times Cited: 30
Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
Wei Yu, De Xie, Tetsuya Yamamoto, et al.
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 2, pp. 327-343
Closed Access | Times Cited: 28
State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications
Volker Vallon
American Journal of Hypertension (2024) Vol. 37, Iss. 11, pp. 841-852
Closed Access | Times Cited: 14
How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?
Volker Vallon
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 10, pp. 1565-1573
Closed Access | Times Cited: 13
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Giovanna Gallo, Massimo Volpe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2484-2484
Open Access | Times Cited: 11
Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model
Juliana Mira Hernández, Erin Y. Shen, Christopher Y. Ko, et al.
Cardiovascular Research (2024)
Open Access | Times Cited: 11
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Sha Chen, Qian Wang, Diane Bakker, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 5, pp. 751-772
Open Access | Times Cited: 10
Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets
Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 209-209
Open Access | Times Cited: 9
The effect of Treatment with SGLT2 Inhibitor on Right Ventricular Function in Heart Failure and Low Ejection Fraction patients
Hagar Ibrahim Allam, Khaled El-Rabbat, Moghniuddin Mohammed, et al.
Benha Medical Journal (2025)
Closed Access | Times Cited: 1
Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia‐ exposed human cardiomyocytes through comprehensive multi‐level analysis
Rosaria Benedetti, Ugo Chianese, Chiara Papulino, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond
Kyriakos Dimitriadis, Eleni Adamopoulou, Nikolaos Pyrpyris, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 8, pp. 741-757
Closed Access | Times Cited: 18
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial
Arno A. van de Bovenkamp, Kiki T. J. Geurkink, Frank T. P. Oosterveer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2998-3010
Open Access | Times Cited: 17
Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure
Barbora Judita Kasperová, Miloš Mráz, Petr Svoboda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top